Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 2 Interventional

SPI-1005 Treatment in Moderate COVID-19 Patients

ClinicalTrials.gov ID: NCT04484025

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04484025. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.

Study identification

NCT ID
NCT04484025
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 2
Enrollment
60 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 12, 2021 (Actual)
Primary completion
Dec 31, 2023 (Estimated)
Completion
Dec 31, 2023 (Estimated)
Last update posted
Oct 3, 2023

2021 – 2023

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Yale University New Haven Connecticut 06510 —
St. Luke's Cystic Fibrosis Center of Idaho Boise Idaho 83702 —
Kansas University Medical Center Kansas City Kansas 66160 —
Washington University in St. Louis St Louis Missouri 63130 —
Duke University Durham North Carolina 27710 —
Wake Forest University Winston-Salem North Carolina 27109 —
University of Texas Southwestern Dallas Texas 75390 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04484025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2023 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.